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The available information about BSC for patients with NSCLC of the four published studies result in annual therapy costs per patient of 17,365 -50,882 € with median costs of 29,261 €. Due to specific characteristics of the different international health care systems, the cost calculation for some kinds of treatments had to be adjusted to fit into the german reimbursement system. In addition, the analysis of the GermanOncology database shows that in Germany, most treatments referring to BSC are provided on an outpatient basis. This leads to significantly lower annual costs than in other international health care systems. 
INTRODUCTION
In the treatment of advanced non-small-cell lung cancer (NSCLC) a cure with anticancer therapy is usually not achievable. For these patients supportive treatments are the treatments of choice including the management of disease-related symptoms in consequence of primary tumour growth or frequently occurring metastases. These kinds of treatments are commonly referred to as "best supportive care" (BSC). However, only a few international studies give valid information about costs caused by BSC.
METHODS
The database of the GermanOncology network contains information about the entire course of treatment including the medication of primary disease, radiotherapy, number of outpatient specialist visits, length of hospitalisation, type and number of diagnostic and laboratory procedures. In addition, international studies from Scotland, Great Britain, the USA and the Netherlands were examined. In order to make comparisons, these results were transferred into the german reimbursement system for health care services. The calculation for annual costs of treatment is based on methods of the Institute for Quality and Efficiency in Healthcare (IQWiG) in Germany.
AIM
Median age: 70 years calculated annual costs = costs of BSC duration of therapy (in days) * 365
